Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bayer looking into established drugs strategy

Bayer is looking into future options for the established drugs business, partly because of price pressure in China, the German company’s head of pharmaceuticals said.

Read More »

Two drugmakers to pay in U.S. charity kickback probe

Astellas and Amgen will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients’ out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications.

Read More »

Novartis Poaches GSK Veteran as New Sandoz CEO

GlaxoSmithKline veteran Richard Saynor is coming home to Sandoz after being named the new chief executive officer of the Novartis subsidiary.

Read More »

Novartis shares rise after lifting 2019 profit outlook

Novartis raised the company’s 2019 profit target, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval in May 2019.

Read More »

UK-Based Accelerator Start Codon Launches with Investment from Genentech and Others

Start Codon launched in Cambridge, England with funding from keystone investors including Cambridge Innovation Capital, Babraham Bioscience Technologies, Genentech, Jonathan Milner and Ian Tomlinson.

Read More »

Eli Lilly Sells Two Legacy Drugs and Manufacturing Facility for $375 Million

Lilly inked a deal with Eddingpharm for the rights to two legacy antibiotic medicines and a manufacturing facility in Suzhou, China.

Read More »

Nocion Therapeutics Launches With $27 Million to Focus on Chronic Cough and Pain

Nocion Therapeutics launched in Cambridge, Mass., with a $27 million series A raise this week.

Read More »

Talaris Rebrands With New Leadership Team

Privately held Talaris Therapeutics secured $100 million in a Series A financing round as the company undergoes a rebranding with a new leadership team.

Read More »

Arrakis to Create New Class of rSM Oncology Drugs

With a $75 million infusion of new financing, Massachusetts-based Arrakis Therapeutics will focus the company’s pipeline on oncology and genetically validated targets in other diseases.

Read More »

Gilead teams up with insitro for experimental NASH treatments

Gilead Sciences Inc. will partner with privately held insitro to develop therapies for a fatty liver disease called NASH.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom